Create a narrative

Akebia Therapeutics Community

NasdaqCM:AKBA Community

1 Narratives written by author
0 Comments on narratives written by author
32 Fair Values set on narratives written by author

Akebia Therapeutics

AN

AnalystConsensusTarget

AnalystConsensusTarget

Consensus Narrative from 4 Analysts

Expanding Dialysis Access Will Unlock New CKD Treatment Frontiers

Key Takeaways Expanded access and rapid adoption of Vafseo position Akebia for significant revenue growth and increased market share within the CKD anemia treatment landscape. Strong payer coverage, promising clinical developments, and prudent financial management support sustained profitability and enable investment in pipeline innovation.

US$7.50

FV

58.5% undervalued

20.54%

Revenue growth p.a.

0

0

18

4 days ago